Influence of ensitrelvir or nirmatrelvir/ritonavir on tacrolimus clearance in kidney transplant recipients: a single-center case series

• Main Authors: Hanako Naganawa (Author), Yoshiki Katada (Author), Shunsaku Nakagawa (Author), Keisuke Umemura (Author), Hiroki Ishimura (Author), Moto Kajiwara (Author), Hiroki Endo (Author), Mitsuhiro Sugimoto (Author), Yurie Katsube (Author), Kinuka Kotani (Author), Saki Ohta (Author), Daiki Hira (Author), Masahiro Tsuda (Author), Yuki Kita (Author), Takashi Kobayashi (Author), Tomohiro Terada (Author)
• Format: Book
• Published: BMC, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Among the oral antivirals used for treating patients with mild-to-moderate novel coronavirus disease 2019 (COVID-19), nirmatrelvir/ritonavir (NMV/RTV) and ensitrelvir (ESV) are inhibitors of cytochrome P450 (CYP) 3A, and therefore, can cause drug-drug interactions with concomitan...